A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged ≥ 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens.
Phase of Trial: Phase II/III
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Barasertib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms SPARK-AML1
- Sponsors AstraZeneca
- 28 May 2014 The number of treatment arms changed from 3 to 2. The study now comprises of 2 arms: Arm-1- AZD 11521 and Arm-2- Cytarabine. The deleted arm is: AZD 11521+Cytarabine.
- 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Apr 2013 Results of Part I of the study (n=77) published in Cancer.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History